Article

Associations between radiographic characteristics and change in renal function following partial nephrectomy using 24-hour creatinine clearance.

Department of Urology, Mayo Clinic, Rochester, MN.
Canadian Urological Association journal = Journal de l'Association des urologues du Canada (Impact Factor: 1.66). 02/2011; 5(1):45-8. DOI: 10.5489/cuaj.10011
Source: PubMed

ABSTRACT Radiographic characteristics may be associated with the degree of renal function preservation following partial nephrectomy. The purpose of this study was to determine the impact of preoperative radiographic variables on change in renal function using 24-hour urine creatinine clearance (uCrCl).
Patients with partial nephrectomy performed from November 2003 to 2008 were enrolled in the study. Serum creatinine and 24-hour urine was collected preoperatively and at 3, 6 and 12 months postoperatively. Computed tomography or magnetic resonance imaging was used to determine tumour size, tumour location and renal volume.
Of the 36 patients, median age was 62 (range 30-78) and 21 (58%) were male. The mean tumour diameter was 2.8±1.4 cm. Twenty-two (61%) tumours were located at the renal pole and 11 (31%) were endophytic. Overall, mean preoperative uCrCl was 88.8±34.2 mL/min and mean postoperative uCrCl was 82.8±33.6 mL/min (6.8%; p < 0.01). On multivariable analysis, no single characteristic was associated with a clinically prohibitive decrease in renal function (-9.4% if endophitic, p = 0.06; -0.57% per cm diameter, p = 0.73; and -6.9% if located at the renal pole, p = 0.15). The total renal volume was also not significantly associated with renal function change (-1.1% per 100 cc, p = 0.86).

0 Bookmarks
 · 
64 Views
  • Source
    The Journal of Urology. 172(6):2483.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Elective nephron-sparing surgery (NSS) for renal cell carcinoma (RCC) < 4 cm has been accepted as alternative to radical nephrectomy (RN). However, NSS for tumours > 4 cm is controversial. We present our experiences and long-term oncologic outcome of RCC > 4 cm treated with NSS in a retrospective single-institutional analysis of 69 patients. Between 1975 and 2004, elective NSS was performed in 368 patients at our institution, including 69 patients with sporadic, nonmetastatic RCC > 4 cm. Overall and cancer-specific survivals were estimated using the Kaplan-Meier method. Complications were seen in nine patients (13.0%). After a mean follow-up of 6.2 yr (median, 5.8 yr) seven patients (10.1%) had died, none of them of tumour-related causes. Tumour recurrence was detected in four patients (5.8%). The 5-yr overall survival probability was 94.9%. The 10-yr and 15-yr overall survival rates were both 86.7%. Cancer-specific survival was 100% after 5, 10, and 15 yr. Selected patients with localized RCC even > 4 cm can be treated with elective NSS providing optimal long-term outcome. The surgeon's decision for organ-preserving surgery should depend on tumour localisation and technical feasibility rather than on tumour size.
    European Urology 06/2006; 49(6):1058-63; discussion 1063-4. · 10.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Efficacy of formulas calculating creatinine clearance (CrCl) to determine renal function eligibility (CrCl > 60 mL/min) for cisplatin-based chemotherapy has not been examined adequately in the bladder cancer population. We hypothesize these formulas may underestimate measured CrCl, and therefore the eligibility for cisplatin-based chemotherapy. A database of 208 patients with unresectable or metastatic bladder cancer treated on protocol at Memorial Sloan-Kettering Cancer Center (New York, NY) with cisplatin-based chemotherapy between 1983 and 1994 was examined retrospectively. The association between measured and calculated CrCl and the ability to complete three cycles (minimum therapeutic) of chemotherapy was examined. Baseline measured CrCl was less than 60 mL/min in 16% compared with 12% to 44% using various formulas. Concordance between calculated and measured CrCl less than 60 mL/min was poor (range of kappa, 0.14 to 0.38). In patients older than age 65, 22% had a measured CrCl less than 60 mL/min, compared with 10% to 63% calculated using various formulas. Overall, 80% completed at least three cycles of cisplatin-based chemotherapy. The ability to complete at least three cycles was statistically significantly related with a measured CrCl more than 60 mL/min (P = .02), but not with calculated CrCl more than 60 mL/min. Current formulas estimating CrCl tend to underestimate measured CrCl, especially in those older than 65 years. Depending on the formula used, up to 44% who actually received cisplatin-based chemotherapy based on measured CrCl would be deemed ineligible at present, potentially affecting survival outcomes. Methodology for determining CrCl and/or renal eligibility for cisplatin-based chemotherapy in patients with bladder cancer should be re-examined.
    Journal of Clinical Oncology 08/2006; 24(19):3095-100. · 18.04 Impact Factor

Full-text

Download
0 Downloads
Available from